Net Asset Value and Portfolio Update

RNS Number : 2900J
Law Debenture Corp PLC
04 December 2018
 

Net Asset Value

 

The Law Debenture Corporation p.l.c. announces that its Net Asset Value ("NAV") with borrowings at par and including fair value of IPS businesses on 30 November 2018 was 646.88 pence per share (ex income) and 660.11 pence per share (cum income).  With the Corporation's long term debt stated at fair value, the NAV was 631.64 pence per share (ex income) and 644.87 pence per share (cum income).  The mid-market price at the close of business on 30 November 2018 was 564.00 pence per share. 

 

In accordance with listing rule 15.6.8, The Law Debenture Corporation p.l.c. announces that it has no investments in other UK listed investment companies that require to be disclosed. Its top ten holdings, including all holdings with a value greater than 5% of the Corporation's gross assets as at 30 November 2018 are set out below.

 

Top 10 Holdings

 

The top 10 holdings in the investment portfolio as at 30 November 2018 were:

 

 

Rank

 

Name of Holding

% of portfolio (excl. cash)

1.

Royal Dutch Shell

4.39

2.

GlaxoSmithKline

2.73

3.

HSBC

2.57

4.

BP

2.44

5.

Rolls Royce

2.05

6.

Senior

2.02

7.

Stewart Investors Pacific

1.99

8.

Rio Tinto

1.96

9.

Prudential

1.88

10.

Hiscox

1.83

 

Geographical Split of investment portfolio

 

 

Region

% of portfolio

UK

61

Europe

8

North America

9

Japan

1

Other Pacific

4

Other

1

Cash and Fixed Interest

16



TOTAL

100

 

Released by The Law Debenture Corporation p.l.c., Fifth Floor, 100 Wood Street, London, EC2V 7EX (contact Ian Bowden, Company Secretariat, 020 7696 5285).

 

 

The Law Debenture Corporation p.l.c. LEI number - 2138006E39QX7XV6PP21


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLLFSRFSLVIIT
UK 100